Products for Research Use Only

PF-03654764

CAT: 0804-HY-123812Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-123812Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PF-03654764 is an orally active, selective histamine H3 receptor antagonist with Ki values of 1.2 nM and 7.9 nM for human H3 and rat H3 in whole cell assay, respectively. The combination of PF-03654764 and Fexofenadine has the potential for allergic rhinitis research[1][2].
CAS Number
935840-35-0
UNSPSC
12352005
Target
Histamine Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/pf-03654764.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
O=C([C@@H]1C[C@@](C2=CC(F)=C(CN3CCCC3)C=C2)(F)C1)NCC(C)C
Molecular Formula
C20H28F2N2O
Molecular Weight
350.45
References & Citations
[1]Travis T Wager, et al. Discovery of two clinical histamine H (3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4- (pyrrolidinylmethyl) phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4- (pyrrolidin-1-ylmethyl) phenyl]-N- (2-methylpropyl) cyclobutanecarboxamide (PF-03654764) . J Med Chem. 2011 Nov 10;54 (21) :7602-20.|[2]Michelle L North, et al. Add-on histamine receptor-3 antagonist for allergic rhinitis: a double blind randomized crossover trial using the environmental exposure unit. Allergy Asthma Clin Immunol. 2014 Jul 3;10 (1) :33.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
H3 Receptor